2 reports of this reaction
1.4% of all LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE reports
#17 most reported adverse reaction
INJECTION SITE ERYTHEMA is the #17 most commonly reported adverse reaction for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, manufactured by Aurohealth LLC. There are 2 FDA adverse event reports linking LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE to INJECTION SITE ERYTHEMA. This represents approximately 1.4% of all 142 adverse event reports for this drug.
Patients taking LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE who experience injection site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE ERYTHEMA is a less commonly reported adverse event for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, but still significant enough to appear in the safety profile.
In addition to injection site erythema, the following adverse reactions have been reported for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE:
The following drugs have also been linked to injection site erythema in FDA adverse event reports:
INJECTION SITE ERYTHEMA has been reported as an adverse event in 2 FDA reports for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE ERYTHEMA accounts for approximately 1.4% of all adverse event reports for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, making it a notable side effect.
If you experience injection site erythema while taking LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.